TBK1-IN-1
CAS No. 1292310-49-6
TBK1-IN-1( MDK10496 | MDK10496 | MDK10496 | IKKε-IN-1 )
Catalog No. M11183 CAS No. 1292310-49-6
TBK1-IN-1 is a potent, ATP-competitive TBK1 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 188 | In Stock |
|
| 5MG | 188 | In Stock |
|
| 10MG | 306 | In Stock |
|
| 25MG | 487 | In Stock |
|
| 50MG | 646 | In Stock |
|
| 100MG | 830 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTBK1-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTBK1-IN-1 is a potent, ATP-competitive TBK1 inhibitor.
-
DescriptionTBK1-IN-1 is a potent, ATP-competitive TBK1 inhibitor, dose-dependently inhibits pIRF3(S386) in Panc 05.04 cells with IC50 of 1.8 nM; inhibits IRF3 nuclear translocation with IC50 of 95 nM, but does not significantly inhibits cell proliferation in some NSCLC, pancreatic, and colorectal cell lines.
-
In VitroTBK1/IKKε-IN-2 (Cmpound #1) inhibits TBK1 biochemical function in Ulight kinase assay at 5 and 250 μM ATP concentration with IC50s of0.6 and 2.6 nM, rsespectively. TBK1/IKKε-IN-2 inhibits IKKε biochemical function in Ulight kinase assay at 10 μM ATP with an IC50 of 3.9 nM. The IC50 of TBK1/IKKε-IN-2 in the Panc 02.13 proliferation assay is 5 μM.
-
In Vivo——
-
SynonymsMDK10496 | MDK10496 | MDK10496 | IKKε-IN-1
-
PathwayImmunology/Inflammation
-
TargetIκB kinase (IKK)
-
RecptorIκB kinase (IKK)
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number1292310-49-6
-
Formula Weight457.5243
-
Molecular FormulaC26H27N5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 21.5 mg/mL
-
SMILESN#CC1=CC(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)=CC=C1OC5CCOCC5
-
Chemical NameBenzonitrile, 5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-2-[(tetrahydro-2H-pyran-4-yl)oxy]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Muvaffak A, et al. Mol Cancer Res. 2014 Jul;12(7):1055-66.
molnova catalog
Cart
sales@molnova.com